H.C. Wainwright raised the firm’s price target on IceCure Medical (ICCM) to $2.50 from $2 and keeps a Buy rating on the shares after the FDA granted marketing authorization the De Novo application for ProSense cryoablation system for the local treatment of breast cancer.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ICCM:
- IceCure Medical’s ProSense® Receives FDA Approval for Breast Cancer Treatment
- Icecure Medical Ltd trading resumes
- IceCure Medical receives FDA marketing authorizationf or ProSense cryoablation
- Icecure Medical Ltd trading halted, news pending
- IceCure Medical Showcases ProSense® Success at EUSOBI Congress 2025